PortfoliosLab logoPortfoliosLab logo
MDT vs. BMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MDT vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MDT achieves a -11.18% return, which is significantly lower than BMY's 10.36% return. Over the past 10 years, MDT has outperformed BMY with an annualized return of 2.10%, while BMY has yielded a comparatively lower 0.72% annualized return.


MDT

1D
1.80%
1M
5.52%
6M
-12.52%
YTD
-11.18%
1Y
-3.70%
3Y*
1.97%
5Y*
-5.21%
10Y*
2.10%

BMY

1D
-0.62%
1M
1.93%
6M
5.32%
YTD
10.36%
1Y
28.77%
3Y*
1.83%
5Y*
1.02%
10Y*
0.72%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MDT vs. BMY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MDT
Medtronic plc
-11.18%24.05%0.28%9.58%-22.55%-9.79%5.70%27.34%15.18%15.90%
BMY
Bristol-Myers Squibb Company
10.36%0.11%15.81%-26.14%18.98%2.88%0.41%27.74%-12.90%7.71%

Correlation

The correlation between MDT and BMY is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.32

Correlation (3Y)
Calculated over the trailing 3-year period

0.33

Correlation (5Y)
Calculated over the trailing 5-year period

0.35

Correlation (10Y)
Calculated over the trailing 10-year period

0.37

Correlation (All Time)
Calculated using the full available price history since Dec 31, 1981

0.33

Fundamentals

Market Cap

MDT:

$107.36B

BMY:

$117.58B

EPS

MDT:

$3.73

BMY:

$3.56

PE Ratio

MDT:

22.50

BMY:

16.15

PEG Ratio

MDT:

11.69

BMY:

0.92

PS Ratio

MDT:

2.97

BMY:

2.42

PB Ratio

MDT:

2.18

BMY:

5.86

Total Revenue (TTM)

MDT:

$36.36B

BMY:

$48.48B

Gross Profit (TTM)

MDT:

$23.64B

BMY:

$33.33B

EBITDA (TTM)

MDT:

$9.72B

BMY:

$13.34B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MDT vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDT
MDT Risk / Return Rank: 3737
Overall Rank
MDT Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
MDT Sortino Ratio Rank: 3333
Sortino Ratio Rank
MDT Omega Ratio Rank: 3333
Omega Ratio Rank
MDT Calmar Ratio Rank: 4242
Calmar Ratio Rank
MDT Martin Ratio Rank: 4040
Martin Ratio Rank

BMY
BMY Risk / Return Rank: 7373
Overall Rank
BMY Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
BMY Sortino Ratio Rank: 7070
Sortino Ratio Rank
BMY Omega Ratio Rank: 6666
Omega Ratio Rank
BMY Calmar Ratio Rank: 7979
Calmar Ratio Rank
BMY Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDT vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MDTBMYDifference
Sharpe ratioReturn per unit of total volatility

-1.02

Sortino ratioReturn per unit of downside risk

-1.51

Omega ratioGain probability vs. loss probability

0.99

1.17

-0.17

Calmar ratioReturn relative to maximum drawdown

-0.11

1.95

-2.06

Martin ratioReturn relative to average drawdown

-0.24

4.28

-4.52

MDT vs. BMY - Sharpe Ratio Comparison

The current MDT Sharpe Ratio is -0.14, which is lower than the BMY Sharpe Ratio of 0.88. The chart below compares the historical Sharpe Ratios of MDT and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MDT vs. BMY - Drawdown Comparison

The maximum MDT drawdown since its inception was -57.63%, smaller than the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for MDT and BMY.


Loading charts...

Drawdown Indicators


MDTBMYDifference

Max Drawdown

Largest peak-to-trough decline

-57.63%

-72.03%

+14.40%

Max Drawdown (1Y)

Largest decline over 1 year

-28.90%

-12.53%

-16.37%

Max Drawdown (3Y)

Largest decline over 3 years

-28.90%

-36.02%

+7.12%

Max Drawdown (5Y)

Largest decline over 5 years

-45.10%

-47.67%

+2.57%

Max Drawdown (10Y)

Largest decline over 10 years

-45.10%

-47.67%

+2.57%

Current Drawdown

Current decline from peak

-27.43%

-16.20%

-11.23%

Average Drawdown

Average peak-to-trough decline

-16.57%

-22.37%

+5.80%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.88%

5.73%

+7.15%

Volatility

MDT vs. BMY - Volatility Comparison

Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY) have volatilities of 8.91% and 8.93%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MDTBMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.91%

8.93%

-0.02%

Volatility (6M)

Calculated over the trailing 6-month period

17.95%

18.73%

-0.78%

Volatility (1Y)

Calculated over the trailing 1-year period

22.38%

27.76%

-5.38%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

22.21%

24.28%

-2.07%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.35%

25.37%

-2.02%

Dividends

MDT vs. BMY - Dividend Comparison

MDT's dividend yield for the trailing twelve months is around 3.40%, less than BMY's 4.36% yield.


PositionTTM20252024202320222021202020192018201720162015
BMY
Bristol-Myers Squibb Company
4.36%4.60%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%
MDT
Medtronic plc
3.40%2.95%3.49%3.34%3.44%2.39%1.95%1.87%2.15%2.24%2.34%1.88%

Financials

MDT vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between Medtronic plc and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


7.00B8.00B9.00B10.00B11.00B12.00B13.00B20222023202420252026
9.81B
11.49B
(MDT) Total Revenue
(BMY) Total Revenue
Values in USD except per share items

MDT vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Medtronic plc and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

55.0%60.0%65.0%70.0%75.0%20222023202420252026
75.9%
70.2%
Portfolio components
MDT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Medtronic plc reported a gross profit of 7.44B and revenue of 9.81B. Therefore, the gross margin over that period was 75.9%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.

MDT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Medtronic plc reported an operating income of 1.56B and revenue of 9.81B, resulting in an operating margin of 16.0%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.

MDT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Medtronic plc reported a net income of 1.24B and revenue of 9.81B, resulting in a net margin of 12.7%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.


Frequently Asked Questions


MDT and BMY have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BMY has higher volatility (8.93%) compared to MDT (8.91%). In terms of maximum drawdown, MDT dropped -57.63% vs BMY's -72.03%.

BMY currently has the higher Sharpe Ratio (0.88 vs -0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MDT and BMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer